AMLX Q3 2022 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMLXAmylyx Pharmaceuticals, Inc.

$1B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$345,000

Gross Profit

$173,00050.1% margin

Operating Income

-$55M-15849.6% margin

Net Income

-$54M-15581.4% margin

EPS (Diluted)

$-0.92

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$43M

Free Cash Flow

-$44M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$181M

Total Liabilities

$37M

Stockholders' Equity

$144M

Cash & Equivalents

$108M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$345,000	$0	—
Gross Profit	$173,000	$0	—
Operating Income	-$55M	-$23M	-138.6%
Net Income	-$54M	-$23M	-132.3%